# Reduce Risk for Crohn's Disease Patients

> **NCT02852694** · PHASE4 · COMPLETED · sponsor: **PIBD-Net** · enrollment: 192 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Methotrexate
- **DRUG:** Adalimumab
- **DRUG:** Azathioprine / 6 Mercaptopurine

## Key facts

- **NCT ID:** NCT02852694
- **Lead sponsor:** PIBD-Net
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-28
- **Primary completion:** 2021-06-14
- **Final completion:** 2021-06-14
- **Target enrollment:** 192 (ACTUAL)
- **Last updated:** 2025-01-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02852694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02852694, "Reduce Risk for Crohn's Disease Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02852694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*